文献速递乳腺癌

复发性ERCC3截短突变赋予乳腺癌中等风险

A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.
PubMed 文献 · Cancer Discov · 2016-09-21

研究在德系犹太人背景的BRCA野生型乳腺癌患者外显子组中反复观察到ERCC3截短突变c.325C>T:p.Arg109*,细胞实验显示该突变导致蛋白表达降低和功能减弱,病例对照比较显示该突变与乳腺癌风险显著相关,尤其在雌激素受体阳性亚组。

要点

  • ERCC3截短突变c.325C>T:p.Arg109*在BRCA野生型德系犹太人乳腺癌患者中反复出现。
  • 该突变在细胞水平导致ERCC3蛋白表达降低及DNA修复功能减弱。
  • 病例对照比较显示该突变与乳腺癌风险相关,雌激素受体阳性亚组关联更明显。

核心结论

  • 功能显著的复发性ERCC3突变在遗传隔离人群中增加乳腺癌风险。
  • 突变细胞系在体外暴露于DNA损伤剂后存活率降低。
  • 核苷酸切除修复基因如ERCC3的突变可能成为部分遗传性乳腺癌的潜在治疗靶点,类似于同源修复缺陷背景下的肿瘤。

研究设计与样本

  • 研究对德系犹太人血统、BRCA野生型乳腺癌患者的外显子组进行测序,反复观察到ERCC3截短突变c.325C>T:p.Arg109*。
  • 在ERCC3缺陷或CRISPR/Cas9编辑的细胞系中建模该突变,并检测UVC暴露或IlludinS处理后的表现。
  • 比较该复发性突变在超过6,500条乳腺癌病例染色体和6,800例德系犹太人对照中的频率。

主要发现

  • 在ERCC3缺陷或CRISPR/Cas9编辑的细胞系中,该突变导致蛋白表达降低并伴随功能减弱(亚效等位基因效应)。
  • 在ERCC3缺陷细胞中过表达突变蛋白仅部分挽救其DNA修复缺陷表型。
  • 病例对照比较显示该突变与乳腺癌风险显著相关(ORBC=1.53,ORER+=1.73),雌激素受体阳性亚组P<0.007。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Known gene mutations account for approximately 50% of the hereditary risk for breast cancer. Moderate and low penetrance variants, discovered by genomic approaches, account for an as-yet-unknown proportion of the remaining heritability. A truncating mutation c.325C>T:p.Arg109* (R109X) in the ATP-dependent helicase ERCC3 was observed recurrently among exomes sequenced in BRCA wild-type, breast cancer-affected individuals of Ashkenazi Jewish ancestry. Modeling of the mutation in ERCC3-deficient or CRISPR/Cas9-edited cell lines showed a consistent pattern of reduced expression of the protein and concomitant hypomorphic functionality when challenged with UVC exposure or treatment with the DNA alkylating agent IlludinS. Overexpressing the mutant protein in ERCC3-deficient cells only partially rescued their DNA repair-deficient phenotype. Comparison of frequency of this recurrent mutation in over 6,500 chromosomes of breast cancer cases and 6,800 Ashkenazi controls showed significant association with breast cancer risk (ORBC = 1.53, ORER+ = 1.73), particularly for the estrogen receptor-positive subset (P < 0.007). SIGNIFICANCE: A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267-75. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 1197.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Vijai J, Topka S, Villano D, et al. A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discov. 2016. PMID: 27655433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。